ImmunityBio, Inc. (IBRX)
10.28
+1.00
(+10.83%)
USD |
NASDAQ |
Oct 02, 16:00
10.30
+0.02
(+0.15%)
After-Hours: 20:00
ImmunityBio Net Income (Quarterly) : -230.39M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -230.39M |
| March 31, 2026 | -632.80M |
| December 31, 2025 | -61.96M |
| September 30, 2025 | -67.27M |
| June 30, 2025 | -92.57M |
| March 31, 2025 | -129.67M |
| December 31, 2024 | -59.18M |
| September 30, 2024 | -85.75M |
| June 30, 2024 | -134.58M |
| March 31, 2024 | -134.13M |
| December 31, 2023 | -233.41M |
| September 30, 2023 | -95.64M |
| June 30, 2023 | -138.21M |
| March 31, 2023 | -116.58M |
| December 31, 2022 | -108.33M |
| September 30, 2022 | -111.16M |
| June 30, 2022 | -94.84M |
| March 31, 2022 | -103.00M |
| December 31, 2021 | -91.55M |
| September 30, 2021 | -88.43M |
| June 30, 2021 | -89.38M |
| March 31, 2021 | -80.48M |
| December 31, 2020 | -32.13M |
| September 30, 2020 | -21.78M |
| Date | Value |
|---|---|
| June 30, 2020 | -20.09M |
| March 31, 2020 | -18.38M |
| December 31, 2019 | -15.64M |
| September 30, 2019 | -15.58M |
| June 30, 2019 | -16.68M |
| March 31, 2019 | -17.88M |
| December 31, 2018 | -17.34M |
| September 30, 2018 | -23.64M |
| June 30, 2018 | -27.73M |
| March 31, 2018 | -27.52M |
| December 31, 2017 | -24.49M |
| September 30, 2017 | -23.97M |
| June 30, 2017 | -23.45M |
| March 31, 2017 | -24.52M |
| December 31, 2016 | -24.24M |
| September 30, 2016 | -31.90M |
| June 30, 2016 | -34.00M |
| March 31, 2016 | -30.68M |
| December 31, 2015 | -76.82M |
| September 30, 2015 | -42.65M |
| June 30, 2015 | -84.58M |
| March 31, 2015 | -4.63M |
| December 31, 2014 | -2.735M |
| March 31, 2014 | -1.158M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Moderna, Inc. | -782.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 51.24M |
| Total Expenses (Quarterly) | 281.62M |
| EPS Diluted (Quarterly) | -0.2194 |
| Enterprise Value | 11.70B |
| Gross Profit Margin (Quarterly) | 90.82% |
| Profit Margin (Quarterly) | -449.6% |
| Earnings Yield | -9.42% |
| Normalized Earnings Yield | -5.293 |